Vaxart Inc. Stock
Vaxart Inc. Stock
The price for the Vaxart Inc. stock decreased slightly today. Compared to yesterday there is a change of -€0.002 (-0.710%).
Our community identified positive and negative aspects for Vaxart Inc. stock for the coming years. 2 users see the criterium "Worthwhile Investment for the next years" as a plus for the Vaxart Inc. stock. On the other hand our users think that "General Risks" could be a problem in the future.
Pros and Cons of Vaxart Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
S********** s********
Cons
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Vaxart Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Vaxart Inc. | -0.710% | -0.639% | -0.356% | -49.821% | -58.457% | -71.193% | -95.333% |
| Larimar Therapeutics Inc. | 3.660% | 8.974% | 18.056% | -40.351% | -8.602% | -5.028% | -81.027% |
| Achieve Life Sciences Inc. | -2.030% | -2.889% | -4.332% | -2.152% | 8.415% | 59.975% | -38.160% |
| aTyr Pharma Inc | - | -2.459% | 3.478% | -79.483% | -83.192% | -70.545% | -88.558% |
Comments
Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) had its "outperform" rating re-affirmed by analysts at William Blair.
Show more
Ratings data for AVIR provided by MarketBeat
News
Vaxart Revenue Jumps 520% in Fiscal Q2
Vaxart (OTC:VXRT), a biotechnology company focused on developing oral tablet vaccines for infectious diseases, reported its second quarter results on August 13, 2025. The standout headline was a
